IN RESPONSE:
We agree with Dr. Thorp that it is always preferable to use the most accurate equation available and to use repeated measures of eGFR to classify persons with respect to kidney function. The incremental benefit of using the CKD Epidemiology Collaboration eGFR equation (1) and multiple eGFR measurements spaced at least 3 months apart (2) is worthy of consideration but would be unlikely to affect our conclusion-that incorporating information on proteinuria would improve the prognostic power of the current staging system for CKD.
Culturally Appropriate Storytelling to Improve Blood Pressure
TO THE EDITOR: I found Houston and colleagues' article (1) to be quite interesting. I feel certain that the use of storytellers from the patient population was critical to the success of their intervention. What the article lacked, and what I think that the success of the intervention can be attributed to, was the role of positive deviance.
The concept of positive deviance has been defined as follows:
[I]n every community there are certain individuals or groups [the positive deviants] whose uncommon behaviors and strategies enable them to find better solutions to problems than their peers, while having access to the same resources and facing similar or worse challenges (2) .
In other words, we don't need to discover new approaches to help patients deal with their chronic diseases. Somewhere out there are other patients with the same diseases and life conditions who have somehow already figured things out for themselves and are
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Letters achieving better results. It is up to us as a health care community to help our patients discover these practices and facilitate their application to our patients' own circumstances. The positive deviance approach has been successfully applied to childhood malnutrition (3); hand hygiene (4); and, in my institution, transmission of methicillinresistant Staphylococcus aureus (5) .
I believe that the storytellers in Houston's and colleagues' article represented positive deviants in the community. Whether through videos, dialogues, social networking, or any other means, the more we help to connect the positive deviants with the broader patient population, the more the very persons whose behaviors need to change can themselves discover the positive deviants. 
Jeffrey Cohn, MD, MHCM

Addressing Missing Data in Clinical Trials
TO THE EDITOR: We read with interest Fleming's excellent article (1), which calls attention to the problem of missing data in clinical research. In the past, patient withdrawal from clinical trials has not received the attention that it deserves as a potential source of bias.
In many trials, insufficient attempts have been made to retain patient participation in clinical trials after study treatment has been discontinued, compromising the integrity of an unbiased intentionto-treat efficacy analysis. As Fleming notes, there is a need to distinguish between nonadherence, when patients have discontinued the study treatment, and nonretention, when patients decline to participate further in the observation schedule. The latter scenario should be decreased as much as possible to allow an unbiased intention-totreat analysis under minimal assumptions.
However, the phenomenon of missing data will remain an issue even if Fleming's advice is strictly implemented. Clinical situations always will occur in which patients change their minds about adherence to study procedures. For example, patients with cancer may become discouraged if their disease seems to progress and may no longer wish to endure the extra time and effort needed to remain a study participant. Other traditional clinical indications for high withdrawal rates from studies include psychiatric disease and obesity.
Methods are being developed that improve statisticians' ability to account for biases introduced by missing data that avoid the simplifications assumed by traditional regression methods. Techniques using causal inference and semiparametric targeted estimation have been shown to provide unbiased and efficient estimators of the desired treatment effect under much less stringent assumptions than those on which current methods rely (2-6). Finally, investigators may actively encourage study participants to complete the trial in which they are enrolled; however, this encouragement may raise ethical issues in that the study investigators may be perceived as being coercive.
The problem of missing data is likely to remain an issue in clinical investigation that should be addressed with all of the tools available to the clinical research community.
Mark van der Laan, PhD
Todd J. Lorenz, MD Orinda, CA 94563
Medical Management of the Acute Radiation Syndrome
TO THE EDITOR:
The nuclear accident at the Fukushima power station in Japan, which reminded us of the nightmare of Hiroshima and Nagasaki, raised serious international concerns about radiation exposure. Stable iodine (for example, potassium iodide) is indicated only as a thyroid-blocking agent to prevent the uptake of radioactive iodine; however, persons living within 1000 miles of Fukushima frantically tried to obtain potassium iodide (1) because they believed that it was a general radioprotective agent and a "magic bullet" in the event of a nuclear accident.
Current recommendations from guidelines on potassium iodide therapy derive almost exclusively from observational studies on the incidence of thyroid cancer in children after the accident at Chernobyl (2, 3) . These data are the best evidence currently available, and the recommendations state that the risk for thyroid cancer in adults exposed to radioactive iodine is minimal. This conclusion seems appropriate, because many adult patients with hyperthyroidism have received radioactive iodine therapy to treat their condition. Persons older than 20 years who are exposed to radioactive iodine are at little risk for thyroid cancer, whereas persons older than 40 years are at virtually no risk (4) . Moreover, the use of potassium iodide for prophylaxis of thyroid cancer is a legitimate concern for children and pregnant and lactating women but not for other adults. After the Chernobyl disaster, 7 million adults in Poland took potassium iodide against the recommendations of the government (5) . Because the window for prophylactic administration of potassium iodide is limited, health care officials should ensure that this agent is promptly available to persons who would most benefit from it during nuclear accidents and should avoid its overuse.
Rumiko Shimazawa, PhD Masayuki Ikeda, MD Nagasaki University Graduate School of Biomedical Sciences Nagasaki 852-8523, Japan
Potential Conflicts of Interest: None disclosed.
